GSK

The study demonstrates the effectiveness of the adjuvanted RSV vaccine in people over 60 years of age.

CompilationStudy shows effectiveness of adjuvanted vaccine RSVPreF3 OA respiratory syncytial virus (RSV) in people over 60 years of age and…

3 weeks ago

GSK is starting a study to test the cost-effectiveness of its RSV vaccine in Spanish adults.

GSK has launched the Efficacy of Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Adults in Spain study1, which aims to…

3 weeks ago

86% of the population underestimate the risk of contracting shingles

Compilation. A GSK-sponsored survey of 3,500 adults over 50 in 12 countries estimated knowledge participants about the risk and severity…

9 months ago